Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B - Trial NCT05905731
Access comprehensive clinical trial information for NCT05905731 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing 302 Hospital and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing 302 Hospital
Timeline & Enrollment
Phase 1
Jun 01, 2023
Jun 01, 2026
Primary Outcome
Safety evaluation of HBV-TCR T cell treatment
Summary
This is a single center, single arm, open label study to assess the safety, tolerability and
 effectiveness of the autologous HBV specific T cell receptor (HBV-TCR) redirected T cells in
 patients with chronic hepatitis B with ongoing with nucleos(t)ide analogue (NUC) treatment.
 This study will be conducted sequentially starting with Stage-1, followed by Stage-2.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05905731
Non-Device Trial